VECTORMUNE® FP MG is a genetically engineered, live Fowl Pox virus vaccine for use in chickens. The Fowl Pox virus has been genetically modified to express key protective Mycoplasma gallisepticum (MG) antigens. This vaccine is presented in a freeze-dried preparation.
VECTORMUNE® FP-MG AND VECTORMUNE® FP-MG + AE:
INNOVATIVE DISEASE CONTROL
VECTORMUNE® FP-MG and VECTORMUNE® FP-MG + AE are genetically engineered live Fowl Pox virus vaccins that allow the Fowl Pox virus to express key protective Mycoplasma gallisepticum antigens. The vaccine combines the safety of the Fowl Pox vaccine with the protection induced by the MG antigens.
This illustration shows the two genes which are removed from the DNA of MG and which are inserted into the DNA of the Fowl Pox virus. These genes express key protective antigens of MG.
VECTORMUNE® FP MG is recommended for wing web application to healthy, susceptible chickens eight weeks of age or older, but at least four weeks prior to the onset of egg production. VECTORMUNE® FP MG is indicated as an aid in the prevention of Fowl Pox and Mycoplasma gallisepticum infections. Chickens receiving this vaccine must not have been previously exposed to Fowl Pox virus or vaccine due to interference with immunity following vaccination.